Zosano Pharma Corporation announced the peer-reviewed publication of a post-hoc analysis of its pivotal Phase 2/3 (ZOTRIP) study in Headache: The Journal of Head and Face Pain, titled 'Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult to Treat Migraines'. In this post-hoc analysis, researchers examined the efficacy of Qtrypta™ in treating subsets of patients whose migraines have traditionally been difficult-to-treat and have been associated with poorer outcomes when treated with oral medications. Migraine characteristics including severe pain, duration of migraine of more than 2 hours, awakening with migraine, and the presence of nausea are established factors that predict a poorer response to traditional migraine treatment. Results from these post-hoc analyses using the same clinical endpoints of pain freedom and most bothersome symptom (MBS) at 2 hours from the ZOTRIP study demonstrated patients with these difficult-to-treat migraine characteristics had uniformly better headache responses compared to patients who received placebo.